Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P000009/S124

Ilivia Neo 7 DR-T 429529; Intica Neo 7 DR-T 429558; Intica Neo 5 DR-T 429568

Biotronik, Inc. · Decision date Sep 25, 2026

MEDTECHLEDGER EXPLANATIONP000009/S124

What did the FDA approve?

Biotronik, Inc. received an FDA approval decision dated 2026-09-25 for three devices listed under PMA supplement P000009/S124: Ilivia Neo 7 DR-T 429529, Intica Neo 7 DR-T 429558 and Intica Neo 5 DR-T 429568. The supplement sits under the original PMA P000009 because the identifier matches. FDA records the reason as a change to design, components, specifications or materials, and categorizes the products as dual-chamber implantable defibrillators under product code MRM in the cardiovascular specialty.

The only stated purpose in the supplied fields is «the next generation of the Home Monitoring Service Center (HMSC)». That wording does not identify which hardware, software or components changed, what the change affects, or any test results, so those specifics remain absent. The approval covers the supplement, not a fresh approval of the whole system. It documents a regulatory decision, not independent evidence of safety or clinical effectiveness.

FDA approval order statement

the next generation of the Home Monitoring Service Center (HMSC)
Regulatory pathway
PMA supplement
Supplement type
Normal 180 Day Track
Clinical specialty
Cardiovascular
Decision date
Sep 25, 2026
FDA change category
Change Design/Components/Specifications/Material

FDA source record · MedtechLedger’s explanation describes the recorded change.

Regulatory record facts

Identifier
P000009/S124
Regulatory pathway
PMA supplement
Product code
MRM
Decision code
APPR
Decision date
Sep 25, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: DEFIBRILLATOR, IMPLANTABLE, DUAL-CHAMBER.

Product code
MRM
FDA device class
3

For the original device and its historical approval scope, see PMA P000009. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P000009 · Original PMA

    PHYLAX AV ICD SYSTEM

  2. P000009/S124 received

    Application receipt date recorded by FDA.

  3. P000009/S130 · Related supplement

    PSW 2601.U, NEO 2601.U, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T

  4. P000009/S133 · Related supplement

    Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aura DR-T, Acticor 7 DR-T, Rivacor 7 DR-T, Rivacor 5 DR-T

  5. P000009/S124 · FDA decision

    Normal 180 Day Track

  6. P000009/S132 · Related supplement

    Acticor Sky DR-T 481987; Rivacor Sky DR-T 481982; Rivacor Rise DR-T 482018; Rivacor Aura DR-T 482014

  7. P000009/S134 · Related supplement

    Intica Neo 7 DR-T DF-1 ProMRI, Intica Neo 5 DR-T DF-1 ProMRI

  8. P000009/S135 · Related supplement

    Ilivia Neo 7 DRT, Intica Neo 7 DRT, Intica Neo 5 DRT, Acticor Sky DR-T, Rivacor Sky DR-T, Rivacor Rise DR-T, Rivacor Aur

Timeline entries are records held by MedtechLedger for P000009. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P000009

Explore the linked device profile

Other records with product code MRM

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Biotronik, Inc.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6024 Jean Rd., Lake Oswego, OR, 97035

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records